The compound at the heart of the work is taraxasterol, a pentacyclic triterpenoid extracted from the roots of the common dandelion, Taraxacum officinale. Taraxasterol has long attracted attention for its antioxidant, anti-inflammatory, and anti-apoptotic activities, and it features in several traditional liver-protective herbal formulations. Yet its clinical promise has been strangled by biopharmaceutical realities. The molecule barely dissolves in water, crosses the intestinal wall poorly, and is actively pumped back out of gut cells by P-glycoprotein, a well-known efflux transporter. The research team, led by Zimin Cai and colleagues at Guizhou Medical University, quantified these barriers precisely. In a Caco-2 cell monolayer model mimicking the intestinal epithelium, taraxasterol showed an apparent permeability coefficient of just 0.79 × 10⁻⁶ cm/s. Adding verapamil, a P-glycoprotein inhibitor, boosted its transport roughly 3.6-fold, confirming the efflux problem. In mice, the absolute oral bioavailability of free taraxasterol measured a dismal 6.4 percent.

To attack the solubility problem first, the team turned to nanocrystal technology, which shrinks drug particles to the nanometer scale to dramatically increase surface area and dissolution rate. They prepared taraxasterol nanocrystals using three candidate stabilizers: poloxamer 407, polyvinyl alcohol, and D-α-tocopherol polyethylene glycol succinate, better known as TPGS, an FDA-approved excipient with a hidden talent. TPGS inhibits P-glycoprotein, meaning it can simultaneously stabilize the nanocrystals and silence the efflux pump that would otherwise expel the drug from intestinal cells. At an optimized stabilizer concentration of 1 percent, the TPGS-stabilized nanocrystals measured roughly 148 nanometers in diameter with a narrow size distribution. They also reduced the lattice energy of the crystalline drug, and dissolution testing showed the payoff: while free taraxasterol achieved only 25.6 percent cumulative dissolution over 24 hours, the TPGS nanocrystals reached 88.4 percent, a 3.45-fold improvement. In transport studies, the TPGS formulation raised apparent permeability 2.6-fold and significantly increased uptake by hepatocytes, the liver cells that ultimately need the drug.

But dissolution alone was not enough, and the researchers knew it. Orally delivered nanocrystals face a gauntlet of further obstacles: the acidic, enzyme-rich stomach, the rapidly renewing mucus layer, and the tight junctions that seal the gaps between epithelial cells. Their answer was a mucoadhesive micropatch built from a polyelectrolyte complex of chitosan and carbopol, two oppositely charged polymers that bind electrostatically. The bilayer patch uses ethyl cellulose as a waterproof backing and the chitosan-carbopol complex as the adhesive layer. When hydrated in the intestine, the patch swells into a gel-like network that physically confines the nanocrystals, creating a diffusion barrier that moderates release and prevents aggregation. As the matrix gradually erodes, intact nanocrystals are progressively freed. Infrared spectroscopy and thermal analysis confirmed the electrostatic complex formation, and scanning electron microscopy showed that nanocrystal-loaded patches had smooth, homogeneous surfaces, while patches loaded with free drug displayed ugly crystalline deposits. Over 24 hours, the nanocrystal patches released 80.75 percent of their payload, compared with a mere 23.58 percent for free-drug patches.

The absorption experiments revealed an elegant dual mechanism. In permeation studies across excised porcine intestinal mucosa, the nanocrystal-loaded polyelectrolyte patches achieved the highest cumulative transport of any formulation. In Caco-2 models, including a mucus-containing co-culture that better mimics the real intestinal environment, the patches boosted permeability through two complementary routes. Transcellular uptake rose thanks to nanocrystal internalization and TPGS-mediated efflux suppression. Paracellular transport increased because the chitosan component transiently opened the tight junctions, a process the team verified by measuring transepithelial electrical resistance, which dropped in a time-dependent manner and recovered after patch removal. Immunofluorescence staining showed downregulation of the tight junction proteins ZO-1 and claudin-4, with chitosan identified as the primary contributor to this reversible modulation. Crucially, the opening was temporary, and cell viability remained above 85 percent across all tested concentrations, indicating the barrier disruption does not come at the cost of tissue damage.

To make sure the patches actually reach the intestine rather than sticking in the stomach, the researchers packaged twenty micropatches into a single enteric-coated capsule. In simulated gastric fluid at pH 1.2, the capsules stayed intact for at least two hours; transferred to intestinal conditions at pH 6.8, they disintegrated within fifteen minutes. A magnesium stearate coating prevented the released patches from clumping together. In vivo fluorescence imaging in mice told a striking story: while free dye and plain nanocrystals were swept through the gastrointestinal tract within hours, the micropatch capsules produced strong, persistent signals in the small intestine for up to 12 hours after administration. The patches were seen adhering to the luminal side of the intestinal mucosa, visibly swollen, forming a localized drug depot that maintains a high concentration gradient driving absorption.

The pharmacokinetic consequences were dramatic. Compared with free taraxasterol, the full capsule system produced a 3.1-fold increase in total drug exposure and a 5.8-fold rise in peak plasma concentration, along with a prolonged half-life and reduced clearance. Even more importantly for a liver disease, tissue distribution analysis showed the highest and most sustained drug levels in the liver itself, with hepatic enrichment persisting over 12 hours. This liver-targeting profile means therapeutic concentrations actually reach the site of injury, rather than diffusing uselessly into other organs.

With delivery solved, the team put the platform to the test in two mouse models of liver injury. In the intrinsic model, mice received acetaminophen; in the idiosyncratic model, they received the isoniazid-rifampicin combination. Treatment with the nanocrystal micropatch capsules outperformed both free taraxasterol and plain nanocrystals, and matched or exceeded silymarin, a clinically established hepatoprotective drug used as the positive control. Serum markers of liver damage, including ALT, AST, LDH, alkaline phosphatase, total bile acids, and total bilirubin, all fell significantly, and histological examination showed restored hepatic architecture. Blank capsules without the drug showed no protective effect, confirming the benefit came from taraxasterol itself, not the carrier. The formulation also cut reactive oxygen species and malondialdehyde, restored glutathione and superoxide dismutase, suppressed the inflammatory cytokines IL-1β, IL-6, and TNF-α, and reduced apoptotic cell death, with no detectable toxicity in blood counts or major organs.

To explain these effects mechanistically, the researchers employed network pharmacology, cross-referencing predicted taraxasterol targets against genes linked to both forms of drug-induced liver injury. The analysis identified 80 shared targets concentrated in three pathological axes: oxidative stress, inflammation, and apoptosis. Western blot validation in injured mouse livers confirmed the prediction. The formulation most potently activated the Nrf2/HO-1 antioxidant defense pathway, suppressed stress-activated JNK phosphorylation, and dampened the Bax/Bcl-2 ratio and caspase-3 activation that drive mitochondrial apoptosis. In essence, the delivery platform amplifies the compound’s intrinsic multi-target pharmacology simply by getting enough of it to the liver.

The authors are candid about the work’s limitations: the studies were prophylactic rather than therapeutic, long-term toxicity remains untested, and manufacturing scalability has yet to be proven. Still, the significance of the platform extends well beyond one dandelion molecule. By integrating nanocrystallization, a functional stabilizer that blocks efflux, mucoadhesive polyelectrolyte patches that transiently open tight junctions, and enteric coating for site-specific release, the team has assembled a generalizable blueprint for rescuing poorly soluble, poorly permeable natural products from formulation purgatory. For the many herbal compounds with intriguing pharmacology but hopeless bioavailability, that blueprint could be the difference between laboratory curiosity and real medicine.

Subject of Research: A nanocrystal-mucoadhesive micropatch oral delivery platform enhancing taraxasterol bioavailability for protection against drug-induced liver injury

Article Title: Boosting oral bioavailability of taraxasterol via a nanocrystal-mucoadhesive micropatch platform for potent multi-mechanistic protection against drug-induced liver injury

Article References: Cai, Z., Zhao, H., Wei, M., Cheng, Z., He, H., Xu, J., Xu, S., Huang, J., Xiao, T., Peng, J., Sun, R., Du, Q., & Chen, Y. (2026). Boosting oral bioavailability of taraxasterol via a nanocrystal-mucoadhesive micropatch platform for potent multi-mechanistic protection against drug-induced liver injury. Materials Today Bio, 41, Article 103694. https://doi.org/10.1016/j.mtbio.2026.103694

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103694

Keywords: taraxasterol, drug-induced liver injury, nanocrystals, oral drug delivery, mucoadhesive micropatch, TPGS, chitosan, carbopol, Nrf2/HO-1 pathway, acetaminophen, bioavailability, hepatoprotection

Orally disintegrating films, or ODFs, are thin sheets that melt rapidly against the oral mucosa, releasing their payload for absorption without the need to swallow. Conventional ODFs rely almost exclusively on hydrophilic polysaccharides such as pullulan, hydroxypropyl methylcellulose, and pregelatinized starch, which disintegrate quickly; published examples include hydroxypropyl cellulose films that vanish in water in about 12.5 seconds and hydroxypropyl methylcellulose formulations that break down in roughly 43 seconds. But these matrices carry little nutritional value, and protein hydrolysate alternatives are prohibitively expensive. Soy protein isolate, a widely available and inexpensive plant protein with excellent film-forming ability and a rich amino acid profile, seemed like an obvious candidate, except that its dense, flexible molecular packing causes films to disintegrate sluggishly in water, sometimes lagging far behind their polysaccharide competitors.

The team’s answer was β-cyclodextrin, a cyclic oligosaccharide with a hydrophobic interior cavity and a hydrophilic, hydroxyl-covered exterior. Cyclodextrins are workhorses in food and pharmaceutical science, used to emulsify, solubilize, mask unpleasant flavors, and protect sensitive bioactive compounds. Previous work by some of the same authors had shown that β-cyclodextrin could accelerate the disintegration of soy protein films by disrupting the tight packing of protein chains. The new study asked whether the molecule could do double duty: remodel the protein network for rapid release while also protecting ergothioneine, a sulfur-containing antioxidant first isolated in 1909 from the fungus Claviceps purpurea and produced by edible fungi and cyanobacteria.

Ergothioneine was a demanding guest. Its unusually low redox potential of −60 millivolts makes it resistant to autoxidation, and studies have shown it outperforms glutathione at scavenging hydroxyl radicals, peroxyl radicals, and singlet oxygen. Yet antioxidant activity in ergothioneine-containing systems is known to decline during thermal processing and storage, likely through oxidative degradation. The researchers cast films by dissolving 2.0 grams of soy protein isolate in water at 75 degrees Celsius, adding 10 milligrams of ergothioneine, 0.7 grams of D-sorbitol as a plasticizer, and β-cyclodextrin at 0, 5, 10, and 15 percent of the dry protein weight, then drying the solutions in Petri dishes at 40 degrees Celsius for eight hours.

Microscopy revealed how dramatically the additive reshaped the material. The pristine soy protein film was rough and inhomogeneous, riddled with micropores and aggregated particulate domains, while adding ergothioneine alone smoothed the surface, apparently by promoting the unfolding of protein polypeptide chains. The real transformation came at 10 percent β-cyclodextrin, where the films displayed an extremely smooth, dense, defect-free surface organized into a continuous reticular network. The authors attribute this to hydrogen bonding between the cyclodextrin’s abundant hydroxyl groups and the protein network, which suppresses pore formation during drying. At 15 percent, however, the strategy backfired: bright, angular crystalline aggregates appeared across the surface, evidence that excess cyclodextrin had exceeded its solubility limit and phase-separated into β-CD-rich crystalline domains, shattering the structural continuity of the protein matrix.

Those structural changes translated directly into performance. The water contact angle, a measure of surface wettability, fell from 63.77 degrees in the control film to 36.28 degrees at 10 percent cyclodextrin, reflecting a far more hydrophilic surface that welcomes water penetration. Tensile strength climbed from 10.37 megapascals in the control to 12.15 megapascals at the optimal loading, and elongation at break rose from 3.462 to 4.376 percent, meaning the films became both stronger and more flexible. Then came the headline result: in vitro disintegration time dropped from 31.67 seconds in the control to 15.46 seconds at 10 percent cyclodextrin, a 45 to 52 percent improvement across the cyclodextrin-containing formulations, comfortably meeting the sub-60-second benchmark for fast-disintegrating films. Intriguingly, the 15 percent formulation showed no significant further gain, because its added thickness lengthened the path water had to travel, canceling out its extra hydrophilicity.

The loading data told a similarly encouraging story. High-performance liquid chromatography showed that ergothioneine loading efficiency rose from 66.83 percent in films without cyclodextrin to 76.33 percent at the 10 percent level, with loading capacity peaking at 2.16 micrograms per milligram of film. Relative standard deviations across replicate films stayed below 4 percent, confirming that the solvent casting method produces reproducible, uniformly dosed films. Each standard 15-by-15-millimeter dosing unit carried about 16.21 micrograms of ergothioneine in the optimal formulation. Surface pH values for all films ranged from 5.55 to 6.48, safely within the range tolerated by oral tissue, and mucoadhesive forces were essentially unchanged at moderate additive levels, reaching 0.69 newtons only in the phase-separated 15 percent formulation, where crystalline protrusions increased contact area.

The protective half of the dual function emerged under stress. The team sealed films in ordinary plastic bags and stored them for 28 days at 40 degrees Celsius, 75 percent relative humidity, under continuous fluorescent light to simulate accelerated oxidative aging. Films containing ergothioneine alone watched their DPPH radical scavenging activity collapse from 83.47 percent on day zero to 40.86 percent by day 28, with ABTS activity falling in parallel from 85.21 to 41.74 percent. Films with 10 percent cyclodextrin retained 60.57 percent DPPH activity and 60.68 percent ABTS activity over the same period, significantly better than every other formulation. Spectroscopic characterization supported the mechanism: X-ray diffraction showed the amorphous protein film acquiring the characteristic crystalline peaks of β-cyclodextrin, while Fourier-transform infrared spectroscopy revealed strengthened hydrogen bonding bands at 3288, 1641, and 1537 reciprocal centimeters, along with new peaks marking the cyclodextrin skeleton. Thermogravimetric analysis showed the maximum decomposition temperature rising steadily with cyclodextrin loading, from 300.28 degrees Celsius in the control to a peak of 314.63 degrees, confirming a more thermally robust composite.

The authors are careful about how far the interpretation can go. Because the antioxidant assays measure total radical scavenging of the entire film matrix rather than residual ergothioneine concentration directly, and because no inclusion complex between cyclodextrin and ergothioneine was demonstrated, the improved retention may reflect reduced oxidative exposure through intermolecular interactions and a denser matrix rather than the specific stabilization of individual ergothioneine molecules. The disintegration tests also used distilled water rather than simulated saliva, and all evaluations were in vitro. Future work employing HPLC or LC-MS quantification of ergothioneine, phase-solubility analysis, differential scanning calorimetry, and two-dimensional NMR is needed to pin down the molecular fate of the antioxidant during storage.

Even with those caveats, the implications are considerable. The study breaks the disintegration barrier that has kept soy protein out of serious consideration for orally disintegrating films, and it does so with a cheap, food-grade cyclodextrin that simultaneously improves mechanical strength, thermal stability, and antioxidant retention. For the food and pharmaceutical industries, the platform suggests a practical route to delivering sensitive bioactive compounds, from ergothioneine to other oxidation-prone nutraceuticals, in a fast-dissolving, plant-protein-based format that adds nutritional value instead of diluting it. If longer-term storage studies and in vivo safety testing bear out the accelerated results, the humble soybean may find itself at the leading edge of oral thin-film technology, one 15-second melt on the tongue at a time.

Subject of Research: Development of soy protein isolate-based orally disintegrating films using β-cyclodextrin to enhance disintegration and protect ergothioneine

Article Title: Development of soy protein isolate-based orally disintegrating films: The dual role of β-Cyclodextrin in enhancing disintegration performance and ergothioneine stability

Article References: Zhou, Y., Du, X., Lv, C., Tian, Y., Guo, S., Guo, Z., & Wang, Z. (2026). Development of soy protein isolate-based orally disintegrating films: The dual role of β-Cyclodextrin in enhancing disintegration performance and ergothioneine stability. Food Chemistry: X, 39, Article 104451. https://doi.org/10.1016/j.fochx.2026.104451

Image Credits: AI Generated

DOI: 10.1016/j.fochx.2026.104451

Keywords: orally disintegrating films, soy protein isolate, β-cyclodextrin, ergothioneine, oral drug delivery, antioxidant stability, film disintegration, hydrogen bonding, plant protein, Food Chemistry: X, bioactive compound protection, solvent casting